BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The Obesity Society News - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.theobesitysocietynews.org
X-WR-CALDESC:Events for The Obesity Society News
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261114T114500
DTEND;TZID=America/New_York:20261114T131500
DTSTAMP:20261008T184101Z
CREATED:20260929T160219Z
LAST-MODIFIED:20261008T184101Z
UID:10000007-1794656700-1794662100@www.theobesitysocietynews.org
SUMMARY:The Missing Piece in the Obesity Puzzle: Exploring the Immunobiology of Obesity and the Role of Amylin (CME)
DESCRIPTION:Details \n\n\n\n\n\nGaylord National Harbor\, Riverview Ballroom B \n\n\n\nThis symposium is sponsored by The France Foundation and the American Association of ImmunologistsSupported by: an educational grant from Novo Nordisk. \n\n\n\n\n\n\n\nSpeakers \n\n\n\n\nPresenterDan Bessesen\, MD\, FTOSUniversity of Colorado AnschutzEndocrinology/Metabolism/DiabetesProfessor of Medicine\, Director of the Anschutz Health and Wellness CenterAurora\, CO \n\n\n\nPresenterEmily Goldberg\, MDUniversity of California\, San FranciscoAssistant Professor of PhysiologySan Francisco\, CA \n\n\n\nPresenterW. Timothy Garvey\, MD\, MACE\, FTOSUniversity of Alabama at BirminghamCharles E. Butterworth\, Jr.\, Professor and University ProfessorUAB Diabetes Research CenterFounding PI and Associate DirectorBirmingham\, AL \n\n\n\nPresenterPriya Jaisinghani\, MDNYU Langone Medical Associates—Penn DistrictEndocrinology and Obesity MedicineClinical Assistant ProfessorNew York\, NY \n\n\n\n\nProgram Description \n\n\n\nJoin us for an engaging lunch symposium exploring the inflammatory processes underlying obesity and their implications for treatment. Faculty will examine the role of adipose tissue dysfunction and chronic inflammation in obesity\, along with the effects of current obesity medications on weight\, comorbidities\, and inflammation. \n\n\n\nThe program will also explore amylin physiology and its relationship to obesity\, with a focus on emerging amylin-based therapies\, including amylin receptor agonists and GLP-1/amylin co-agonists. Faculty will discuss the latest evidence\, areas of uncertainty\, and how these approaches may shape the future of obesity care. \n\n\n\nLed by a multidisciplinary panel of experts\, this 90-minute symposium will connect the underlying science of obesity with current and emerging treatment strategies\, offering insights clinicians can apply as the therapeutic landscape continues to evolve. \n\n\n\nDuring this symposium\, you will learn to: \n\n\n\n\nDescribe obesity as a chronic\, progressive disease characterized by adipose tissue dysfunction and chronic low-grade inflammation\, which together contribute to metabolic complications\n\n\n\nRecognize the effects of current obesity medications on obesity-related inflammation and comorbidities\n\n\n\nDescribe how amylin physiology relates to obesity\n\n\n\nAnalyze the potential role of amylin-based therapies in future obesity treatment\n\n\n\n\nEarn free CME! \n\n\n\nLunch will be served. \n\n\n\nRegister today!
URL:https://www.theobesitysocietynews.org/event/sl000027248/
CATEGORIES:Corporate-Supported Symposium (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261115T114500
DTEND;TZID=America/New_York:20261115T131500
DTSTAMP:20261008T161417Z
CREATED:20260930T140556Z
LAST-MODIFIED:20261008T161417Z
UID:10000009-1794743100-1794748500@www.theobesitysocietynews.org
SUMMARY:Bridging Obesity and MASLD Through Metabolic Dysfunction (Non-CME)
DESCRIPTION:Details \n\n\n\n\n\nRiverview Ballroom A \n\n\n\nSupported By: Boehringer Ingelheim Pharmaceuticals\, Inc. \n\n\n\n\n\n\n\nSpeakers \n\n\n\n\nPresenterMazen Noureddin\, MD\, MHScHouston Methodist HospitalProfessor of MedicineSummit and Pinnacle Clinical ResearchChief Scientific Officer and Co-Chairman of the BoardHouston\, TX \n\n\n\nPresenterMichelle Look\, MD\, FAAFP\, DABOMknownwellMedical Director Clinical Research\, Obesity Medicine and Sports Medicine PhysicianSan Diego\, CA \n\n\n\n \n\n\n\n\nProgram Description \n\n\n\nThis program will explore the interconnected relationships between obesity\, metabolic dysfunction\, and MASLD/MASH\, highlighting the role of visceral and hepatic fat in amplifying metabolic dysfunction. Participants will learn why waist circumference–based measures and earlier liver assessment\, including FIB-4\, should be considered integral components of obesity care. Participants will also examine the importance of individualized\, comprehensive care plans that address the diverse needs of people living with obesity.
URL:https://www.theobesitysocietynews.org/event/sl000027048/
CATEGORIES:Corporate-Supported Symposium (Non-CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261115T183000
DTEND;TZID=America/New_York:20261115T210000
DTSTAMP:20261008T171055Z
CREATED:20260930T135547Z
LAST-MODIFIED:20261008T171055Z
UID:10000008-1794767400-1794776400@www.theobesitysocietynews.org
SUMMARY:Obesity in Focus: Today's evidence. Tomorrow's possibilities. (Non-CME)
DESCRIPTION:Details \n\n\n\n\n\nGaylord National Resort & Convention Center\, Exhibit Hall A \n\n\n\nSupported By: Novo \n\n\n\n\n\n\n\nSpeakers \n\n\n\n\nPresenterDomenica Rubino\, MDWashington Center for Weight Management & ResearchFounder and DirectorArlington\, VA \n\n\n\nPresenterJaime Almandoz\, MD\, MBA\, DABOM\, FTOSUniversity of Texas Southwestern Medical CenterProfessor of Medicine and Medical DirectorDallas\, TX \n\n\n\nPresenterAkshay Jain\, MD\, FRCPC\, FACE\, CCD\, ECNU\, DABOMUnity HealthcareClinical Endocrinologist and Medical Director for Clinical TrialsSurrey\, Canada \n\n\n\nPresenterDeborah Horn\, DO\, MPH\, MFOMAUniversity of Texas McGovern Medical School / UT Center for Obesity Medicine and Metabolic PerformanceMedical Director\, Professor of Internal Medicine and SurgeryHouston\, TX \n\n\n\nPresenterThomas Lutz\, Prof. Dr. med. vet.\, PhDInstitute of Veterinary Physiology\, University of ZurichProfessor of Veterinary PhysiologyZurich\, Switzerland \n\n\n\n\nProgram Description \n\n\n\nNovo invites you to our Corporate-Supported Symposium in conjunction with ObesityWeek\, November 14–17\, 2026\, in Washington\, DC\, USA!  \n\n\n\nJoin us on Sunday 15 November\, 6:30-9 pm in Exhibit Hall A\, Gaylord National Resort & Convention Center for an engaging symposium titled ‘Obesity in Focus: Today’s evidence. Tomorrow’s possibilities.’\, exploring the evolving landscape of obesity management\, followed by dinner.  \n\n\n\nChaired by Dr. Jaime Almandoz (USA)\, this symposium will bring together expert faculty to discuss what is making headlines in obesity care. From the latest guideline recommendations and clinical evidence for approved pharmacological treatments to the emerging science of native amylin and amylin analogs\, the programme will combine focused presentations with expert commentary and discussion. Hear from Dr. Deborah Horn (USA) on what is changing in obesity guidelines\, Dr. Akshay Jain (Canada) on the evidence shaping current pharmacological treatment\, Prof. Thomas Lutz (Switzerland) on the biology and mechanism of action of amylin and its potential to complement GLP-1\, and Dr. Domenica Rubino (USA) on emerging evidence for amylin analogs\, including potential effects on weight management.  \n\n\n\nDuring the symposium\, we will explore the following learning objectives:  \n\n\n\n\nReview the evolving obesity treatment landscape\, including current guideline recommendations \n\n\n\nReview recent clinical evidence for approved treatments across different formulations in obesity management\, including weight loss outcomes and body composition​​ \n\n\n\nExplore the biology of amylin\, its mechanism of action\, its uniqueness and potential to be complementary to GLP-1 \n\n\n\nReview emerging clinical evidence for amylin analogs\, including their efficacy and safety\, and potential effects on weight management \n\n\n\n\nWe look forward to seeing you for 75 minutes of expert insights\, emerging evidence and discussion\, before continuing the conversation over dinner. 
URL:https://www.theobesitysocietynews.org/event/sl000027141/
CATEGORIES:Corporate-Supported Symposium (Non-CME)
END:VEVENT
END:VCALENDAR